DNA methylation is a crucial regulator of gene transcription and has been linked to various diseases, including autoimmune diseases and cancers. However, diagnostics based on DNA methylation face challenges due to large feature sets and small sample sizes, resulting in overfitting and suboptimal performance. To address these issues, we propose MIRACLE, a novel interpretable neural network that leverages autoencoder-based multi-task learning to integrate multiple datasets and jointly identify common patterns in DNA methylation. MIRACLE's architecture reflects the relationships between methylation sites, genes, and pathways, ensuring biological interpretability and meaningfulness. The network comprises an encoder and a decoder, with a bottleneck layer representing pathway information as the basic unit of heredity. Customized defined MaskedLinear Layer is constrained by site-gene-pathway graph adjacency matrix information, which provides explainability and expresses the site-gene-pathway hierarchical structure explicitly. And from the embedding, there are different multi-task classifiers to predict diseases. Tested on six datasets, including rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease, psoriasis, and type 1 diabetes, MIRACLE demonstrates robust performance in identifying common functions of DNA methylation across different phenotypes, with higher accuracy in prediction dieseases than baseline methods. By incorporating biological prior knowledge, MIRACLE offers a meaningful and interpretable framework for DNA methylation data analysis in the context of autoimmune diseases.

Iterative Scopes, a pioneer in precision-medicine technologies for gastroenterology, announced that Shrujal Baxi, MD, MPH, has joined its leadership team as Chief Medical Officer. "Having a stellar scientific, medical, and regulatory affairs team is critical to Iterative Scopes' work, and we're very excited to have Dr. Baxi leading these groups," says Jonathan Ng, MBBS, founder and CEO of Iterative Scopes. "As a medical oncologist, Dr. Baxi has witnessed a transformation in oncology that has accelerated the public's understanding of cancer while also fueling precise management of the disease. Data has driven this innovation and knowledge generation, and I look forward to seeing her apply this expertise to our focus on individualized care for people with inflammatory bowel disease." Dr. Baxi specializes in real-world evidence generation, and throughout her career has been involved in multiple clinical trials.

Multi-instance learning (MIL) is widely used in the computer-aided interpretation of pathological Whole Slide Images (WSIs) to solve the lack of pixel-wise or patch-wise annotations. Often, this approach directly applies "natural image driven" MIL algorithms which overlook the multi-scale (i.e. pyramidal) nature of WSIs. Off-the-shelf MIL algorithms are typically deployed on a single-scale of WSIs (e.g., 20x magnification), while human pathologists usually aggregate the global and local patterns in a multi-scale manner (e.g., by zooming in and out between different magnifications). In this study, we propose a novel cross-scale attention mechanism to explicitly aggregate inter-scale interactions into a single MIL network for Crohn's Disease (CD), which is a form of inflammatory bowel disease. The contribution of this paper is two-fold: (1) a cross-scale attention mechanism is proposed to aggregate features from different resolutions with multi-scale interaction; and (2) differential multi-scale attention visualizations are generated to localize explainable lesion patterns. By training ~250,000 H&E-stained Ascending Colon (AC) patches from 20 CD patient and 30 healthy control samples at different scales, our approach achieved a superior Area under the Curve (AUC) score of 0.8924 compared with baseline models. The official implementation is publicly available at https://github.com/hrlblab/CS-MIL.

We included 13 studies on machine learning-based prediction models in IBD encompassing themes of predicting treatment response to biologics and thiopurines, predicting longitudinal disease activity and complications and outcomes in patients with acute severe ulcerative colitis. The most common machine learnings models used were tree-based algorithms, which are classification approaches achieved through supervised learning. Machine learning models outperformed traditional statistical models in risk prediction. However, most models were at high risk of bias, and only one was externally validated.

Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn’s disease (CD), is an idiopathic condition related to a dysregulated immune response to commensal intestinal microflora in a genetically susceptible host. As a global disease, the morbidity of IBD reached a rate of 84.3 per 100,000 persons and reflected a continued gradual upward trajectory. The medical cost of IBD is also notably extremely high. For example, in Europe, it has €3,500 in CD and €2,000 in UC per patient per year, respectively. In addition, taking into account the work productivity loss and the reduced quality of life, the indirect costs are incalculable. In modern times, the diagnosis of IBD is still a subjective judgment based on laboratory tests and medical images. Its early diagnosis and intervention is therefore a challenging goal and also the key to control its progression. Artificial intelligence (AI)-assisted diagnosis and prognosis prediction has proven effective in many fields including gastroenterology. In this study, support vector machines were utilized to distinguish the significant features in IBD. As a result, the reliability of IBD diagnosis due to its impressive performance in classifying and addressing region problems was improved. Convolutional neural networks are advanced image processing algorithms that are currently in existence. Digestive endoscopic images can therefore be better understood by automatically detecting and classifying lesions. This study a...

EndoSoft is pleased to announce that EndoVault 3.2.1.0 All providers using the platform will also have the National Authentication Service for Health (NASH) certificate of security and be on the federated provider directory service, consisting of multiple provider directories in Australia to send secure messages. Argus, the only AI decision support technology that assists clinicians in the detection and sizing of polyps during colonoscopy procedures, has announced a 3-month free trial of their solution. This free trial offers a unique chance to compare detection rates and sizing with and without the assistance of AI. Canada Health Infoway (Infoway) and EndoSoft LLC (EndoSoft) announced today that the EndoVault v3.x solution has achieved Infoway certification under the 2017 Edition of pre-implementation certification requirements.

The tremendous boost in the next generation sequencing and in the omics technologies makes it possible to characterize human gut microbiome (the collective genomes of the microbial community that reside in our gastrointestinal tract). While some of these microorganisms are considered as essential regulators of our immune system, some others can cause several diseases such as Inflammatory Bowel Diseases (IBD), diabetes, and cancer. IBD, is a gut related disorder where the deviations from the healthy gut microbiome are considered to be associated with IBD. Although existing studies attempt to unveal the composition of the gut microbiome in relation to IBD diseases, a comprehensive picture is far from being complete. Due to the complexity of metagenomic studies, the applications of the state of the art machine learning techniques became popular to address a wide range of questions in the field of metagenomic data analysis. In this regard, using IBD associated metagenomics dataset, this study utilizes both supervised and unsupervised machine learning algorithms, i) to generate a classification model that aids IBD diagnosis, ii) to discover IBD associated biomarkers, iii) to find subgroups of IBD patients using k means and hierarchical clustering. To deal with the high dimensionality of features, we applied robust feature selection algorithms such as Conditional Mutual Information Maximization (CMIM), Fast Correlation Based Filter (FCBF), min redundancy max relevance (mRMR) and Extreme Gradient Boosting (XGBoost). In our experiments with 10 fold cross validation, XGBoost had a considerable effect in terms of minimizing the microbiota used for the diagnosis of IBD and thus reducing the cost and time. We observed that compared to the single classifiers, ensemble methods such as kNN and logitboost resulted in better performance measures for the classification of IBD.